Physician

John Matthew Raymond Pierce, M.D.

According to 2025 Medicare claims, John Pierce, M.D. (NPI: 1669799961) practices internal medicine in the Birmingham, AL market, with the plurality of this provider's patient population coming from Jefferson, AL. This provider's primary affiliated billing organization is BIRMINGHAM HEMATOLOGY ONCOLOGY ASSOC LLC (NPI: 1841216389; TIN: 522170293) and primary practice location at 35235-3411.

Pierce's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 314 traditional Medicare patients, billed 105,520 HCPCS/CPT codes, and received $1,834,452 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,218 prescription claims across 361 beneficiaries totaling $4,679,169 in drug costs, led by Jakafi (Ruxolitinib Phosphate). DME data shows 24 claims. Open Payments data shows 144 records totaling $2,974. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $38,342 to $1,834,452. Similarly, Part D prescription costs have risen steadily, from $10,182 to $4,679,169. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	162	523	$38,342
2016	14	25	$1,694
2017	15	29	$2,630
2018	185	30,615	$425,241
2019	396	148,862	$2,271,032
2020	368	149,306	$2,232,450
2021	400	124,086	$1,638,981
2022	342	100,795	$1,150,609
2023	341	122,689	$1,438,154
2024	314	105,520	$1,834,452

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	54	120	$10,182
2016	N/R	15	$2,269
2017	N/R	14	$256
2018	73	148	$87,220
2019	236	1,363	$2,952,769
2020	250	1,643	$3,396,317
2021	247	1,670	$3,676,197
2022	299	2,061	$4,363,412
2023	322	2,215	$4,859,593
2024	361	2,218	$4,679,169

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	30	$1,863
2016	N/R	12	$393
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	14	$43,659
2021	N/R	38	$34,487
2022	N/R	12	$33,281
2023	N/R	N/R	N/R
2024	N/R	24	$35,545

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	86	228	$88
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	107	177	$53
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	156	310	$11
36415	Insertion of needle into vein for collection of blood sample	213	595	$8
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	236	752	$7

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jakafi	Ruxolitinib Phosphate	45	1,350	$778,985
Lenalidomide	Lenalidomide	52	1,428	$715,569
Revlimid	Lenalidomide	45	1,134	$679,433
Pomalyst	Pomalidomide	18	504	$419,308
Calquence	Acalabrutinib Maleate	28	840	$358,818

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J1576	Injection, immune globulin (panzyga), intravenous, non-lyophilized (e.g., liquid), 500 mg	N	N/R	12	$31,589
Q2052	Services, supplies and accessories used in the home for the administration of intravenous immune globulin (ivig)	N	N/R	12	$3,956

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	144	$2,974	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for John Matthew Raymond Pierce, M.D.?

Tedicare shows public-source Medicare data for John Matthew Raymond Pierce, M.D. (NPI 1669799961), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does John Matthew Raymond Pierce, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to John Matthew Raymond Pierce, M.D.?

John Matthew Raymond Pierce, M.D. is linked to BIRMINGHAM HEMATOLOGY ONCOLOGY ASSOC LLC (billing NPI 1841216389) in the available physician profile data.

Does John Matthew Raymond Pierce, M.D. have Open Payments data?

John Matthew Raymond Pierce, M.D. has 144 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.